0

Back to Overcoming Common Barriers Around the Application of Immuno-Oncology in Community Settings
Overcoming Common Barriers Around the Application of Immuno-Oncology in Community Settings

Overcoming Common Barriers Around the Application of Immuno-Oncology in Community Settings

Due to the growing complexity of immuno-oncology (IO) biomarker testing and interpretation, the role of pathologists and laboratory professionals is becoming more central to safe and effective delivery of precision medicine in cancer care. Oncologists are increasingly relying on pathologists for guidance to ensure that the correct PD-L1 test is ordered based on different types of tumor and planned treatment regimens, but it can be challenging to keep up with continuously evolving IO landscape.

In this course, you will learn how to apply the latest science and evidence as you navigate administrative challenges surrounding institutional policies and procedures. You will gain a deeper understanding that surrounds the complexity of PD-L1 testing based on the type of tumor, different antibody assays, and scoring systems. Additionally, you will learn about the practical application of MSI/MMR testing and the potentially emerging role of tumor mutational burden (TMB) when treating patients with checkpoint inhibitor therapy.

The activity offers 1.5 CME, CMLE, or SAMs CME credit.

  • List Price: Free
Item Details:

Due to the growing complexity of immuno-oncology (IO) biomarker testing and interpretation, the role of pathologists and laboratory professionals is becoming more central to safe and effective delivery of precision medicine in cancer care. Their unique perspective on disease processes and access to...

Back to Overcoming Common Barriers Around the Application of Immuno-Oncology in Community Settings
View More View Less

Bought This Bought That ...